Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2011, Vol. 31 Issue (10): 7-11    DOI:
    
Production and Characterization of Anti-OAS1 Monoclonal Antibody
LI Zi1, BAO Xin-chen1, GAO Xiang-dong1, LU Xiao-dong2, XU Chen2
1. College of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China;
2. Beijing Tri-Prime Genetic Engineering Incorporated, Beijing 102600, China
Download: HTML   PDF(602KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Aim: To detect OAS1, its monoclonal antibody was prepared by immune mouse. Methods: BALB/c female mice were immunized with His-OAS1 expressed by E.coli BL21 cells. Monoclonal antibody (McAb) was prepared by hybridoma technology. Identify the purity and characteristics of the selected McAb purified with saturated ammonium sulfate and give preliminary evaluation of the effectiveness of its application, in which SDS-PAGE, ELISA, Western blot and other methods were used. Results: High efficient expression of OAS1 protein in vivo, a McAb can detect the OAS1 was obtained designated as C24-5. The titer of C24-5-McAb was over 9×10-10mol/L, and the affinity constant of C24-5-McAb was 7.66×107 L·mol-1. Conclusion: The preparation of C24-5-McAb is very important to further improve the detection of OAS1.



Key wordsOAS1      Cell fusion      Monoclonal antibody     
Received: 03 May 2011      Published: 25 October 2011
ZTFLH:  Q819  
Cite this article:

LI Zi, BAO Xin-chen, GAO Xiang-dong, LU Xiao-dong, XU Chen. Production and Characterization of Anti-OAS1 Monoclonal Antibody. China Biotechnology, 2011, 31(10): 7-11.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2011/V31/I10/7


[1] Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol, 2005, 5 (3): 215-229.

[2] Gish R G. Current treatment and future directions in the management of chronic hepatitis B viral infection. Clin Liver Dis, 2005, 9 (4): 541-565.

[3] Chebath J, Benech P, Hovanessian A, et al. Four different forms of interferon-induced 2',5'-oligo(A) synthetase identified by immunoblotting in human cells. J Biol Chem, 1987, 262 (8):3852-3857.

[4] Hovanessian A G, Svab J, Marié I, et al. Characterization of 69-and 100-kDa forms of 2-5A-synthetase from interferon-treated human cells. J Biol Chem, 1988, 263(10):4945-4949.

[5] Hovanessian A G. Interferon-induced and double-stranded RNA-activated enzymes: a specific protein kinase and 2',5'-oligoadenylate synthetases. J Interferon Res, 1991,11(4):199-205.

[6] Silverman R H. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol, 2007, 81(23):12720-12729.

[7] 安萍,秦绍明,杨开宇,等. 慢性乙型肝炎病人注射α-干扰素后2-5AS活性动态变化及其临床意义. 天津医药,1995,23(3):147-149. An P,Qin S M,Yang K Y,et al. Tianjin Medical Journal,1995,23(3):147-149.

[8] Studier F W. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif, 2005, 41(1):207-234.

[9] Beatty J D, Beatty B G, Vlahos W G. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods, 1987, 100(1-2):173-179.

[10] Bingfa X, Qinglin F, Hui H, et al. Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo. Pharmacology, 2009, 83(6):323-332.

[11] 吴诗品,苏冬娜.CHB患者PBMC中2-5AS基础活性对IFNα信号分子改变的影响.中华微生物学和免疫学杂志,2006,26(11):1026-1030. Wu S P,Su D N. Chinese Journal of Microbiology and Immunology,2006,26(11):1026-1030.

[1] ZHAO Yan-shu,ZHANG Jin-hua,SONG Hao. Advances in Production of Monoclonal Antibody and Antibody Fragments in Engineered Prokaryotes and Yeast[J]. China Biotechnology, 2020, 40(8): 74-83.
[2] WANG Meng,SONG Hui-ru,CHENG Yu-jie,WANG Yi,YANG Bo,HU Zheng. Accurate Detection of Streptococcus pneumoniae by Using Ribosomal Protein L7 / L12 as Molecular Marker[J]. China Biotechnology, 2020, 40(4): 34-41.
[3] JIANG Yi-fan,JIA Yu,Wang Long,WANG Zhi-ming. The Glycosylation Design and Control of Monoclonal Antibody by Cell Culture[J]. China Biotechnology, 2019, 39(8): 95-103.
[4] LIU Guo-fang,LIU Xiao-zhi,GAO Jian,WANG Zhi-ming. Effects of Host Cell Residual Proteins on the Quality and Their Quality Control of Monoclonal Antibody[J]. China Biotechnology, 2019, 39(10): 105-110.
[5] Jian-wei REN,Jun LI,Shang-ze LI. Human CT55 Protein Prokaryotic Expression and Its Production of Monoclonal Antibody[J]. China Biotechnology, 2018, 38(11): 1-8.
[6] Kai-yun MAO,Yue-lei FAN,Heng-zhe WANG,Da-ming CHEN. Market Competition Pattern of Global PD-1/PD-L1 Monoclonal Antibody[J]. China Biotechnology, 2018, 38(11): 103-115.
[7] Jing-jing SUN,Wei-wei ZHOU,Lei-ming ZHOU,Qiao-hui ZHAO,Gui-lin LI. Advance in Large-Scale Culture of Hybridoma Cells in Vitro[J]. China Biotechnology, 2018, 38(10): 82-89.
[8] WANG Yun-long, ZHAO Er-xia, LI Yu-lin. Expression, Purification and Identification of Thymidine Kinase 1 Recombinant Protein[J]. China Biotechnology, 2017, 37(9): 15-22.
[9] WU Meng-ling, ZHOU Jia-wang, DU Jun. Development and Application of A Double Monoclonal Antibody Sandwich ELISA for the Assay of Nodal[J]. China Biotechnology, 2017, 37(3): 51-57.
[10] LI Min, WU Ri-wei. The Market Overview of Monoclonal Antibodies in Both Domestic and Abroad[J]. China Biotechnology, 2017, 37(3): 106-114.
[11] REN Hua-jing, LIU Xiao-zhi, WANG Zhi-ming, GAO Jian. Progression of Central Nervous System Disease Therapeutic Antibody Drug Application[J]. China Biotechnology, 2016, 36(9): 54-58.
[12] ZHANG Yin-chuan, LIU Meng-meng, ZHANG Ya-ting, GUI Fang, ZHANG Ai-hua, BI Lan, PAN Yong-bin. Construction and Screening of Recombinant Cell Line Expressing Fully-human mAbs against Human IgE[J]. China Biotechnology, 2015, 35(3): 66-74.
[13] WANG Lan, XIA Mao, GAO Kai. The Development and Quality Control of Antibody-Drug Conjugates[J]. China Biotechnology, 2014, 34(4): 85-94.
[14] GAO Kai, XU Zhi-kai, REN Yue-ming, WAN Lan, WANG Jun-zhi, GUO Zhong-ping. Points to Consider for the General Monograph of Monoclonal Antibody Based Biotherapeutics in Chinese Pharamacopeia[J]. China Biotechnology, 2014, 34(1): 127-134.
[15] LI Ming-zhu, HAN Wei-dong, Xing Guang-hui, TENG Zhen-lin, XUE Guo-mei, HOU Chen-rui, RUAN Hong-qiang, CHEN Wei. Research of N Terminal Sequencing Methods for Monoclonal Antibody Pharmaceuticals Blocked by Pyroglutamic Acid[J]. China Biotechnology, 2013, 33(8): 75-83.